Glaucoma research community and FDA look to the future, II: NEI/FDA Glaucoma Clinical Trial Design and Endpoints Symposium: measures of structural change and visual function.
作者信息
Weinreb Robert N, Kaufman Paul L
机构信息
Hamilton Glaucoma Center, University of California, San Diego, La Jolla, California 92093-0946, USA.
出版信息
Invest Ophthalmol Vis Sci. 2011 Oct 4;52(11):7842-51. doi: 10.1167/iovs.11-7895.
Abstract
摘要
相似文献
1
Glaucoma research community and FDA look to the future, II: NEI/FDA Glaucoma Clinical Trial Design and Endpoints Symposium: measures of structural change and visual function.青光眼研究界与美国食品药品监督管理局展望未来，第二部分：美国国立眼科研究所/美国食品药品监督管理局青光眼临床试验设计与终点研讨会：结构变化与视觉功能的测量指标
Invest Ophthalmol Vis Sci. 2011 Oct 4;52(11):7842-51. doi: 10.1167/iovs.11-7895.
2
The glaucoma research community and FDA look to the future: a report from the NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium.青光眼研究界与美国食品药品监督管理局展望未来：来自美国国立眼科研究所/美国食品药品监督管理局药品评价和研究中心青光眼临床试验设计与终点研讨会的报告
Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1497-505. doi: 10.1167/iovs.08-2843.
3
Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium.美国国立眼科研究所/美国食品药品监督管理局眼科临床试验设计与终点研讨会报告。
Invest Ophthalmol Vis Sci. 2008 Feb;49(2):479-89. doi: 10.1167/iovs.07-1132.
4
Use of patient-reported outcomes in medical product development: a report from the 2009 NEI/FDA Clinical Trial Endpoints Symposium.患者报告结局在医疗产品研发中的应用：2009年美国国立眼科研究所/美国食品药品监督管理局临床试验终点研讨会报告
Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6095-103. doi: 10.1167/iovs.10-5627.
5
Home Monitoring for Glaucoma: Current Applications and Future Directions.青光眼的家庭监测：当前应用和未来方向。
Semin Ophthalmol. 2021 May 19;36(4):310-314. doi: 10.1080/08820538.2021.1896759. Epub 2021 Mar 10.
6
Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT.选择性激光小梁成形术与滴眼液治疗新发眼压升高和青光眼的比较：LiGHT RCT。
Health Technol Assess. 2019 Jun;23(31):1-102. doi: 10.3310/hta23310.
7
Report From the NEI/FDA Diabetic Retinopathy Clinical Trial Design and Endpoints Workshop.美国国立眼科研究所/美国食品药品监督管理局糖尿病性视网膜病变临床试验设计与终点研讨会报告
Invest Ophthalmol Vis Sci. 2016 Oct 1;57(13):5127-5142. doi: 10.1167/iovs.16-20356.
8
The Eye Institute of Thrace glaucoma progression diagram (EIT-GPD): incorporating the relationship between visual ability and visual fields.色雷斯眼科学研究所青光眼进展图（EIT-GPD）：纳入视觉能力与视野之间的关系。
Clin Exp Ophthalmol. 2012 May-Jun;40(4):e229-30. doi: 10.1111/j.1442-9071.2011.02701.x. Epub 2011 Nov 4.
9
Development of an 18-Item Measure of Symptom Burden in Patients With Glaucoma From the Collaborative Initial Glaucoma Treatment Study's Symptom and Health Problem Checklist.开发一种用于测量青光眼患者症状负担的 18 项工具，该工具源于合作性初始青光眼治疗研究的症状和健康问题清单。
JAMA Ophthalmol. 2017 Dec 1;135(12):1345-1351. doi: 10.1001/jamaophthalmol.2017.4574.
10
Progress and lack of progress in glaucoma.青光眼的进展与未进展情况
Acta Ophthalmol. 2010 Feb;88(1):3-4. doi: 10.1111/j.1755-3768.2010.01861.x.
引用本文的文献
1
Onset of End-Stage Atrophic Age-Related Macular Degeneration as an End Point-A Delphi Study: Classification of Atrophy Meetings Report 7.以晚期萎缩性年龄相关性黄斑变性的发病为终点——德尔菲研究：萎缩会议报告7分类
Ophthalmol Sci. 2025 Mar 28;5(5):100777. doi: 10.1016/j.xops.2025.100777. eCollection 2025 Sep-Oct.
2
Heterogeneous Visual Function Deficits in Intermediate Age-Related Macular Degeneration: A MACUSTAR Report.中年相关性黄斑变性的异质性视觉功能缺陷：MACUSTAR报告
Ophthalmol Sci. 2025 Jan 13;5(4):100708. doi: 10.1016/j.xops.2025.100708. eCollection 2025 Jul-Aug.
3
Addressing Multiplicity in Retinal Sensitivity Analysis: An Alternative Approach to Assessing Gene Therapy Efficacy in Inherited Retinal Diseases.解决视网膜敏感性分析中的多重性问题：评估遗传性视网膜疾病基因治疗疗效的另一种方法。
Transl Vis Sci Technol. 2025 Mar 3;14(3):25. doi: 10.1167/tvst.14.3.25.
4
High-Resolution Microperimetry for Detecting Glaucomatous Damage: A Prospective Evaluation of Performance.用于检测青光眼性损伤的高分辨率微视野检查：性能的前瞻性评估
Clin Exp Ophthalmol. 2025 Aug;53(6):602-610. doi: 10.1111/ceo.14528. Epub 2025 Mar 24.
5
Ranked Importance of Visual Function Outcome Measures in Choroideremia Clinical Trials.脉络膜视网膜炎临床试验中视觉功能评估结果的重要性排序。
Invest Ophthalmol Vis Sci. 2024 Nov 4;65(13):58. doi: 10.1167/iovs.65.13.58.
6
Dense optic nerve head deformation estimated using CNN as a structural biomarker of glaucoma progression.使用卷积神经网络估计致密视神经头变形作为青光眼进展的结构生物标志物。
Eye (Lond). 2023 Dec;37(18):3819-3826. doi: 10.1038/s41433-023-02623-8. Epub 2023 Jun 17.
7
A potential primary endpoint for clinical trials in glaucoma neuroprotection.青光眼神经保护临床试验的一个潜在主要终点。
Sci Rep. 2023 May 2;13(1):7098. doi: 10.1038/s41598-023-34009-x.
8
Neuroprotection in neurodegenerations of the brain and eye: Lessons from the past and directions for the future.大脑和眼部神经退行性疾病中的神经保护：过去的经验与未来的方向
Front Neurol. 2022 Aug 12;13:964197. doi: 10.3389/fneur.2022.964197. eCollection 2022.
9
Visual Field Endpoints for Neuroprotective Trials: A Case for AI-Driven Patient Enrichment.神经保护试验的视野终点：人工智能驱动的患者选择。
Am J Ophthalmol. 2022 Nov;243:118-124. doi: 10.1016/j.ajo.2022.07.013. Epub 2022 Jul 28.
10
Comparison of machine learning approaches for structure-function modeling in glaucoma.青光眼结构-功能建模中机器学习方法的比较。
Ann N Y Acad Sci. 2022 Sep;1515(1):237-248. doi: 10.1111/nyas.14844. Epub 2022 Jun 21.
本文引用的文献
1
Evaluation of retinal nerve fiber layer progression in glaucoma a prospective analysis with neuroretinal rim and visual field progression.青光眼视盘神经纤维层进展的评估——神经纤维层和视野进展的前瞻性分析。
Ophthalmology. 2011 Aug;118(8):1551-7. doi: 10.1016/j.ophtha.2010.12.035. Epub 2011 Apr 29.
2
Use of patient-reported outcomes in medical product development: a report from the 2009 NEI/FDA Clinical Trial Endpoints Symposium.患者报告结局在医疗产品研发中的应用：2009年美国国立眼科研究所/美国食品药品监督管理局临床试验终点研讨会报告
Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6095-103. doi: 10.1167/iovs.10-5627.
3
Comparison of retinal nerve fiber layer thickness in normal eyes using time-domain and spectral-domain optical coherence tomography.比较时域和频域光学相干断层扫描在正常眼中的视网膜神经纤维层厚度。
Am J Ophthalmol. 2010 Dec;150(6):807-14. doi: 10.1016/j.ajo.2010.06.024.
4
Effect of disease severity and optic disc size on diagnostic accuracy of RTVue spectral domain optical coherence tomograph in glaucoma.疾病严重程度和视盘大小对视盘相干断层扫描诊断青光眼的准确性的影响。
Invest Ophthalmol Vis Sci. 2011 Mar 10;52(3):1290-6. doi: 10.1167/iovs.10-5546. Print 2011 Mar.
5
Predicting the onset of glaucoma: the confocal scanning laser ophthalmoscopy ancillary study to theOcular Hypertension Treatment Study.预测青光眼的发病：青光眼高眼压治疗研究的共焦激光扫描检眼镜辅助研究。
Ophthalmology. 2010 Sep;117(9):1674-83. doi: 10.1016/j.ophtha.2010.03.044. Epub 2010 Jul 14.
6
Reproducibility of peripapillary retinal nerve fiber layer thickness and optic nerve head parameters measured with cirrus HD-OCT in glaucomatous eyes.频域光相干断层扫描测量青光眼患者视盘周围视网膜神经纤维层厚度和视盘参数的重复性。
Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5724-30. doi: 10.1167/iovs.10-5222. Epub 2010 Jun 23.
7
Predicting visual function from the measurements of retinal nerve fiber layer structure.从视网膜神经纤维层结构的测量值预测视觉功能。
Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5657-66. doi: 10.1167/iovs.10-5239. Epub 2010 May 26.
8
Glaucomatous progression in series of stereoscopic photographs and Heidelberg retina tomograph images.一系列立体照片和海德堡视网膜断层扫描图像中的青光眼进展情况。
Arch Ophthalmol. 2010 May;128(5):560-8. doi: 10.1001/archophthalmol.2010.52.
9
Rates of progressive retinal nerve fiber layer loss in glaucoma measured by scanning laser polarimetry.扫描激光偏振光仪测量青光眼患者视网膜神经纤维层进行性丧失的速率。
Am J Ophthalmol. 2010 Jun;149(6):908-15. doi: 10.1016/j.ajo.2010.01.010. Epub 2010 Apr 8.
10
Linking structure and function in glaucoma.青光眼的结构与功能关联。
Prog Retin Eye Res. 2010 Jul;29(4):249-71. doi: 10.1016/j.preteyeres.2010.02.001. Epub 2010 Mar 11.
Zotero 插件